UGT1A1 Polymorphism for Irinotecan Dose Escalation in Patients with BRAF-Mutated Metastatic Colorectal Cancer Treated with First-Line Bevacizumab and FOLFIRI

Table 2

Baseline characteristics of 17 patients with BRAF-mutated mCRC divided into irinotecan escalation and no irinotecan escalation groups.

Characteristic	Group A (irinotecan escalation) (N = 8)	Group B (no irinotecan escalation) (N = 9)	value
Age (years)
Median ± SDa (range)	59 ± 11.9 (36–72)	51 ± 14.6 (35–81)	0.459
Gender			0.057
Male	6 (75%)	2 (22.2%)
Female	2 (25%)	7 (77.8%)
Histology			0.576
WD	0 (0%)	0 (0%)
MD	7 (87.5%)	6 (66.7%)
PD	1 (12.5%)	3 (33.3%)
Site of metastasis			0.959
1	3 (37.5%)	3 (33.3%)
2	3 (37.5%)	4 (44.5%)
≥3	2 (25%)	2 (22.2%)
BMI (kg/m^2)			0.623
Mean ± SDa	23.9 ± 3.47	22.7 ± 5.83
Response			0.697
Complete response	0 (0%)	0 (0%)
Partial response	1 (12.5%)	1 (11.1%)
Stable disease	5 (62.5%)	4 (44.4%)
Progressive disease	2 (25%)	4 (44.4%)
Responder			1.00
Yes	1 (12.5%)	1 (11.1%)
No	7 (87.5%)	8 (88.9%)
DCR			0.62
Yes	6 (75%)	5 (55.6%)
No	2 (25%)	4 (44.4%)